Dennis J Selkoe

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
    Ganesh M Shankar
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
    Nat Med 14:837-42. 2008
  2. ncbi Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
    Dennis J Selkoe
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Nat Cell Biol 6:1054-61. 2004
  3. ncbi Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1
    Tracy L Young-Pearse
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Neural Dev 3:15. 2008
  4. ncbi Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking
    Andreas Weihofen
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Biochemistry 48:2045-52. 2009
  5. ncbi Aph-1 associates directly with full-length and C-terminal fragments of gamma-secretase substrates
    Allen C Chen
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 285:11378-91. 2010
  6. ncbi Functional alterations in memory networks in early Alzheimer's disease
    Reisa A Sperling
    Department of Neurology, Center for Alzheimer s Research and Treatment, Brigham and Women s Hospital, 221 Longwood Avenue, Boston, MA 02115, USA
    Neuromolecular Med 12:27-43. 2010
  7. ncbi A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation
    Olivia I Okereke
    Division of Aging, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Int J Geriatr Psychiatry 24:177-82. 2009
  8. ncbi Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease
    Matthew L Hemming
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Neurobiol Dis 26:273-81. 2007
  9. ncbi A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease
    Weiming Xia
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, HIM 616, 77 Ave Louis Pasteur, Boston, MA 02115, USA
    Arch Neurol 66:190-9. 2009
  10. ncbi Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation
    Soyon Hong
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 31:15861-9. 2011

Detail Information

Publications105 found, 100 shown here

  1. ncbi Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
    Ganesh M Shankar
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
    Nat Med 14:837-42. 2008
    ..We conclude that soluble Abeta oligomers extracted from Alzheimer's disease brains potently impair synapse structure and function and that dimers are the smallest synaptotoxic species...
  2. ncbi Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
    Dennis J Selkoe
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Nat Cell Biol 6:1054-61. 2004
    ..A common theme has arisen in this field: normally-soluble proteins accumulate, misfold and oligomerize, inducing cytotoxic effects that are particularly devastating in the post-mitotic milieu of the neuron...
  3. ncbi Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1
    Tracy L Young-Pearse
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Neural Dev 3:15. 2008
    ....
  4. ncbi Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking
    Andreas Weihofen
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Biochemistry 48:2045-52. 2009
    ..Finally, we find that Miro and Milton expression suppresses altered mitochondrial morphology induced by loss of Pink1 function in cell culture. Our findings suggest that Pink1 functions in the trafficking of mitochondria in cells...
  5. ncbi Aph-1 associates directly with full-length and C-terminal fragments of gamma-secretase substrates
    Allen C Chen
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 285:11378-91. 2010
    ..Taken together, our data suggest a dominant role for Aph-1 in interacting with gamma-secretase substrates prior to their processing by the proteolytic complex...
  6. ncbi Functional alterations in memory networks in early Alzheimer's disease
    Reisa A Sperling
    Department of Neurology, Center for Alzheimer s Research and Treatment, Brigham and Women s Hospital, 221 Longwood Avenue, Boston, MA 02115, USA
    Neuromolecular Med 12:27-43. 2010
    ..Research is ongoing to determine if these early network alterations will serve as sensitive predictors of clinical decline, and eventually, as markers of pharmacological response to potential disease-modifying treatments for AD...
  7. ncbi A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation
    Olivia I Okereke
    Division of Aging, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Int J Geriatr Psychiatry 24:177-82. 2009
    ..In preliminary analyses, we considered the relation of combined lower insulin secretion (c-peptide) and higher insulin--possibly a phenotype for impaired insulin degradation--to cognitive decline...
  8. ncbi Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease
    Matthew L Hemming
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Neurobiol Dis 26:273-81. 2007
    ..Furthermore, we find no change in plaque deposition or in peripheral Abeta levels. Data from these Alzheimer models suggest that captopril and similar ACE inhibitors do not cause Abeta accumulation in vivo...
  9. ncbi A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease
    Weiming Xia
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, HIM 616, 77 Ave Louis Pasteur, Boston, MA 02115, USA
    Arch Neurol 66:190-9. 2009
    ....
  10. ncbi Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation
    Soyon Hong
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 31:15861-9. 2011
    ....
  11. ncbi Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway
    Matthew Townsend
    Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 282:33305-12. 2007
    ....
  12. ncbi Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease
    Matthew L Hemming
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 4:e262. 2007
    ..The objective of this study was to determine if enhancing the clearance of Abeta in the brain by ex vivo gene delivery of an Abeta-degrading protease can reduce amyloid plaque burden...
  13. ncbi Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy
    Wesley Farris
    Center for Neurologic Diseases, Department of Neurology, Harvard Institutes of Medicine, Room 730, Boston, MA 02115, USA
    Am J Pathol 171:241-51. 2007
    ....
  14. ncbi Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors
    Shaomin Li
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 31:6627-38. 2011
    ..Thus, soluble Aβ oligomers at low nanomolar levels present in AD brain increase activation of extrasynaptic NR2B-containing receptors, thereby impairing synaptic plasticity...
  15. ncbi Biochemical and functional interaction of disrupted-in-schizophrenia 1 and amyloid precursor protein regulates neuronal migration during mammalian cortical development
    Tracy L Young-Pearse
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 30:10431-40. 2010
    ....
  16. ncbi Pancortins interact with amyloid precursor protein and modulate cortical cell migration
    Heather C Rice
    Center for Neurologic Diseases, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Development 139:3986-96. 2012
    ..Taken together, these results suggest a biochemical and functional interaction between APP and pancortins, and reveal a previously unidentified role for pancortins in mammalian cortical development...
  17. ncbi gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site
    Patrick C Fraering
    Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 280:41987-96. 2005
    ..Drugs targeting the gamma-secretase nucleotide-binding site represent an attractive strategy for safely treating Alzheimer disease...
  18. ncbi Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration
    Ming Jin
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:5819-24. 2011
    ..We conclude that natural dimers isolated from the AD brain are sufficient to potently induce AD-type tau phosphorylation and then neuritic dystrophy, but passive immunotherapy mitigates this...
  19. ncbi Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein
    Wesley Farris
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Biochemistry 44:6513-25. 2005
    ..Our results identify a novel, catalytically inefficient form of IDE expressed in brain and non-neural tissues and recommend novel regions of the IDE gene in which to search for mutations predisposing patients to AD and DM2...
  20. ncbi Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway
    Ganesh M Shankar
    Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 27:2866-75. 2007
    ..Our approach provides a quantitative cellular model for elucidating the molecular basis of Abeta-induced neuronal dysfunction...
  21. ncbi Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage
    Jay H Chyung
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 280:4383-92. 2005
    ....
  22. ncbi Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers
    Matthew Townsend
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA
    Ann Neurol 60:668-76. 2006
    ..INTERPRETATION: A small, orally available natural product penetrates into the brain in vivo to rescue the memory impairment produced by soluble Abeta oligomers through a mechanism that restores hippocampal synaptic plasticity...
  23. ncbi Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements
    Matthew L Hemming
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Biol 6:e257. 2008
    ..These findings expand our understanding of the mechanisms of substrate selection as well as the diverse cellular processes to which gamma-secretase contributes...
  24. ncbi The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments
    Matthew J LaVoie
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    J Biol Chem 278:34427-37. 2003
    ..Thus, Notch and its cognate ligands are processed by the same molecular machinery and may antagonistically regulate each other's signaling...
  25. ncbi Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies
    Ronit Sharon
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 278:49874-81. 2003
    ..Together with our earlier observations, these results suggest that alphaS-PUFA interactions help regulate neuronal PUFA levels as well as the oligomerization state of alphaS, both normally and in human synucleinopathies...
  26. ncbi Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo
    Dominic M Walsh
    Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Nature 416:535-9. 2002
    ....
  27. ncbi Ten-year change in plasma amyloid beta levels and late-life cognitive decline
    Olivia I Okereke
    Division of Aging and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Ave, Third Floor, Boston, MA 02115, USA
    Arch Neurol 66:1247-53. 2009
    ..Plasma levels of amyloid beta peptide (Abeta) are potential biomarkers of early cognitive impairment and decline and of Alzheimer disease risk...
  28. ncbi Amyloid deposition is associated with impaired default network function in older persons without dementia
    Reisa A Sperling
    Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neuron 63:178-88. 2009
    ....
  29. ncbi A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference
    Tracy L Young-Pearse
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 27:14459-69. 2007
    ..We conclude that full-length APP functions as an important factor for proper migration of neuronal precursors into the cortical plate during the development of the mammalian brain...
  30. ncbi Performance characteristics of plasma amyloid-beta 40 and 42 assays
    Olivia I Okereke
    Division of Aging, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    J Alzheimers Dis 16:277-85. 2009
    ..While these preliminary findings suggest that measuring plasma Abeta(40) and Abeta(42) may be feasible in varied research settings, additional work in this area is necessary...
  31. ncbi Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers
    Matthew Townsend
    Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA
    J Physiol 572:477-92. 2006
    ..We conclude that specific assemblies, particularly timers, of naturally secreted Abeta oligomers are potent and selective inhibitors of certain forms of hippocampal LTP...
  32. ncbi Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution
    Pamela Osenkowski
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    J Mol Biol 385:642-52. 2009
    ..The structure reveals several domains on the extracellular side, three solvent-accessible low-density cavities, and a potential substrate-binding surface groove in the transmembrane region of the complex...
  33. ncbi The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease
    Ronit Sharon
    Center for Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02215, USA
    Neuron 37:583-95. 2003
    ..We conclude that alpha S interacts with PUFAs in vivo to promote the formation of highly soluble oligomers that precede the insoluble alpha S aggregates associated with neurodegeneration...
  34. ncbi Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study
    Mary K Townsend
    Department of Epidemiology, Harvard School of Public Health, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Alzheimer Dis Assoc Disord 26:50-4. 2012
    ....
  35. ncbi Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior
    Dennis J Selkoe
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Behav Brain Res 192:106-13. 2008
    ..A new diagnostic-therapeutic paradigm to successfully address AD and its harbinger, mild cognitive impairment-amnestic type, is emerging...
  36. ncbi Direct and potent regulation of gamma-secretase by its lipid microenvironment
    Pamela Osenkowski
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 283:22529-40. 2008
    ..Taken together, these results demonstrate that membrane lipid composition is a direct and potent modulator of gamma-secretase and that cholesterol, in particular, plays a major regulatory role...
  37. ncbi Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1
    Andreas Weihofen
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Hum Mol Genet 17:602-16. 2008
    ..Finally, we document the influence of Parkin on Pink1 subcellular distribution, providing further evidence for a common pathogenic pathway in recessive PD...
  38. ncbi Identification of beta-secretase (BACE1) substrates using quantitative proteomics
    Matthew L Hemming
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 4:e8477. 2009
    ..These findings expand our understanding of the proteins and cellular processes that BACE1 may regulate, and suggest possible mechanisms of toxicity arising from chronic BACE1 inhibition...
  39. ncbi Dopamine covalently modifies and functionally inactivates parkin
    Matthew J LaVoie
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, 77 Avenue Louis Pasteur, HIM 7th Floor, Boston, Massachusetts 02115, USA
    Nat Med 11:1214-21. 2005
    ....
  40. ncbi Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype
    Irit Rappley
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Neurochem 111:15-25. 2009
    ..Our results provide a detailed and systematic characterization of brain phospholipid composition in mice and identify age-related changes relevant both to Parkinson's disease and to normal aging...
  41. ncbi gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins
    Dominic M Walsh
    Department of Neurology, Harvard Medical School and Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biochemistry 42:6664-73. 2003
    ....
  42. ncbi Effects of membrane lipids on the activity and processivity of purified γ-secretase
    Oliver Holmes
    Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, United States
    Biochemistry 51:3565-75. 2012
    ....
  43. ncbi HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele
    Victor Zota
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women s Hospital, Boston, MA, USA
    J Immunol 183:3522-30. 2009
    ..This new knowledge enables us to explore the basis for understanding the variations in naturally occurring Abeta-reactive T cells and Abeta immunogenicity among humans...
  44. ncbi α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
    Tim Bartels
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 477:107-10. 2011
    ....
  45. ncbi Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation
    W Taylor Kimberly
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    J Neurosci 25:5533-43. 2005
    ..We conclude that endogenous AICD undergoes tight temporal regulation during the differentiation of neurons and is negatively regulated by JNK3 via phosphorylation of APP at Thr668...
  46. ncbi Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s)
    W Taylor Kimberly
    Center for Neurologic Diseases, Brigham and Women's Hospital, and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
    Biochemistry 42:137-44. 2003
    ..These data resolve some of the apparent conflicts and strongly indicate that Notch and APP are proteolyzed by the same enzyme(s)...
  47. ncbi Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein
    Wesley Farris
    Department of Neurology, Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Am J Pathol 164:1425-34. 2004
    ..Our findings have relevance for the emerging genetic evidence suggesting that IDE may be a late-onset AD-risk gene, and for the epidemiological relationships among hyperinsulinemia, DM2, and AD...
  48. ncbi Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface
    Jay H Chyung
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:51035-43. 2003
    ..Our findings are consistent with a role for the gamma-secretase complex in the processing of numerous single-transmembrane receptors at the cell surface...
  49. ncbi Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex
    Patrick C Fraering
    Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Biochemistry 43:323-33. 2004
    ..Taken together, our results demonstrate that Pen-2 interacts with PS-NTF within active gamma-secretase and offer a model for how the components of active gamma-secretase interact physically with each other...
  50. ncbi Preventing Alzheimer's disease
    Dennis J Selkoe
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Science 337:1488-92. 2012
    ..This process will likely position the field for success, but only with much greater investment in all aspects of Alzheimer research and with careful design of future trials...
  51. ncbi LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model
    Babak Nazer
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Neurobiol Dis 30:94-102. 2008
    ..These results implicate LRP as a mediator of Abeta degradation, but indicate that overexpression of LRP or Pgp alone is insufficient for non-proteolytic transcytosis of intact Abeta...
  52. ncbi Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation
    Dominic M Walsh
    Department of Neurology, Harvard Medical School, and Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts 02115-5716, USA
    J Neurosci 25:2455-62. 2005
    ....
  53. ncbi Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo
    Wesley Farris
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4162-7. 2003
    ....
  54. ncbi Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease
    Alon Monsonego
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    J Clin Invest 112:415-22. 2003
    ....
  55. ncbi New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF
    Ting Yang
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Alzheimers Dement 9:99-112. 2013
    ..There is a great need for assays that quantify Aß oligomers with high specificity and sensitivity...
  56. ncbi Environmental novelty activates β2-adrenergic signaling to prevent the impairment of hippocampal LTP by Aβ oligomers
    Shaomin Li
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Neuron 77:929-41. 2013
    ..These mechanistic insights support using prolonged exposure to cognitive novelty and/or oral β-adrenergic agonists to lessen the effects of Aβ accumulation during aging...
  57. ncbi Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly
    Wei Qiao Qiu
    Department of Psychiatry, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Int J Geriatr Psychiatry 22:536-42. 2007
    ..Plasma Amyloid-beta peptide 42 (Abeta42) declines before and soon after the onset of AD, yet the relationship between plasma Abeta42 and depression is unclear...
  58. ncbi Amyloid beta-peptide is produced by cultured cells during normal metabolism: a reprise
    Dennis J Selkoe
    Center for Neurologic Diseases, Harvard Institutes of Medicine, Rm 730, 77 Avenue Louis Pasteur, Boston MA 02115, USA
    J Alzheimers Dis 9:163-8. 2006
    ..Here, I review the background underlying this discovery and then discuss its implications for research on Alzheimer's disease, particularly for the development of disease-modifying therapies...
  59. ncbi Evidence that alpha-synuclein does not inhibit phospholipase D
    Irit Rappley
    Department of Neurology, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biochemistry 48:1077-83. 2009
    ....
  60. ncbi Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death
    Malcolm A Leissring
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Harvard Medical School, Boston, MA 02115, USA
    Neuron 40:1087-93. 2003
    ..Our findings demonstrate that chronic upregulation of Abeta-degrading proteases represents an efficacious therapeutic approach to combating Alzheimer-type pathology in vivo...
  61. ncbi Folding proteins in fatal ways
    Dennis J Selkoe
    Center for Neurologic Diseases, Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Nature 426:900-4. 2003
    ..Understanding some of the principles of protein folding has helped to explain how such diseases arise, with attendant therapeutic insights...
  62. ncbi Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman
    Dennis J Selkoe
    Center for Neurological Diseases, Brigham and Women s Hospital, and the Harvard Center for Neurodegeneration and Repair Boston, Massachusetts, USA
    Neurochem Res 28:1705-13. 2003
    ..Some of these are now reaching the clinic, providing the final and most important test for this hypothetical mechanism of disease...
  63. ncbi Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice
    Cynthia A Lemere
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurobiol Dis 14:10-8. 2003
    ..Most of the Abeta in the serum of the immunized mice was bound to antibodies. We conclude that following active immunization, anti-Abeta antibodies sequester serum Abeta and may increase central nervous system to serum Abeta clearance...
  64. ncbi Alzheimer's disease is a synaptic failure
    Dennis J Selkoe
    Center for Neurologic Diseases, Brigham and Women s Hospital, and the Harvard Center for Neurodegeneration and Repair, Boston, MA 02115, USA
    Science 298:789-91. 2002
    ....
  65. ncbi Deciphering the genetic basis of Alzheimer's disease
    Dennis J Selkoe
    Center for Neurologic Diseases, Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Annu Rev Genomics Hum Genet 3:67-99. 2002
    ..This understanding of the genotype-to-phenotype conversions of familial AD has led to the development of pharmacological strategies to lower amyloid beta-protein levels as a way of treating or preventing all forms of the disease...
  66. ncbi Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease
    Dennis J Selkoe
    Center for Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Harvard Institutes of Medicine, Boston, Massachusetts 02115, USA
    J Clin Invest 110:1375-81. 2002
  67. ncbi Biochemistry. Intramembrane proteases--mixing oil and water
    Michael S Wolfe
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA
    Science 296:2156-7. 2002
  68. ncbi Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate
    William P Esler
    Center for Neurologic Diseases, Brigham and Women's Hospital and Program in Neuroscience, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:2720-5. 2002
    ....
  69. ncbi Proteolysis of chimeric beta-amyloid precursor proteins containing the Notch transmembrane domain yields amyloid beta-like peptides
    Jimin Zhang
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 277:15069-75. 2002
    ..We conclude that gamma-secretase can cleave near the middle of the Notch TMD, that Abeta-like peptides may arise during Notch processing, and that the pre-TMD sequence of the substrate influences recognition or binding by the enzyme...
  70. ncbi Introducing transglutaminase into the study of Alzheimer's disease. A personal look back
    Dennis J Selkoe
    Center for Neurologic Diseases, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, HIM 730, Boston, MA 02115, USA
    Neurochem Int 40:13-6. 2002
  71. ncbi Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics
    Dennis J Selkoe
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Annu Rev Pharmacol Toxicol 43:545-84. 2003
    ....
  72. ncbi Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies
    Michael G Schlossmacher
    Department of Neurology, Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Pathol 160:1655-67. 2002
    ..These results suggest that functional parkin proteins may be required during LB formation...
  73. ncbi Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration
    Brian M Whalen
    Center for Neurologic Diseases, Brigham and Women's Hospital, 65 Landsdowne Street 307A, Cambridge, MA 02139, USA
    Neurobiol Dis 20:254-66. 2005
    ..A similar pattern of degeneration may occur during the preclinical and early clinical phases of Alzheimer's disease...
  74. ncbi Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation
    Chianping Ye
    Department of Medicine at Harvard Medical School, Division of Endocrinology, Brigham and Women's Hospital, Boston, MA 02115, USA
    Neurosci Lett 366:320-5. 2004
    ..These findings suggest that PFs may activate neurons differently than fibrils and lend support to the hypothesis that pre-fibrillar assemblies of Abeta may play an important role in the development of AD-type synaptic deficits...
  75. ncbi Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations
    Nina E Shepardson
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, HIM Room 730, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Arch Neurol 68:1385-92. 2011
    ....
  76. ncbi Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies
    Nina E Shepardson
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arch Neurol 68:1239-44. 2011
    ..Therefore, this first part of our review provides the background and rationale for investigating statins as potential therapeutic agents in patients with AD, the subject of the second part...
  77. ncbi Presenilin: running with scissors in the membrane
    Dennis J Selkoe
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cell 131:215-21. 2007
    ..Here we highlight recent progress in deciphering the role of presenilin/gamma-secretase in biology and medicine and pose key questions for future study...
  78. ncbi Response to: Pardossi-Piquard et al., "Presenilin-Dependent Transcriptional Control of the Abeta-Degrading Enzyme Neprilysin by Intracellular Domains of betaAPP and APLP." Neuron 46, 541-554
    Allen C Chen
    Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medial School, Boston, MA 02115, USA
    Neuron 53:479-83. 2007
  79. ncbi Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain
    Ganesh M Shankar
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Methods Mol Biol 670:33-44. 2011
    ....
  80. ncbi Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease
    Dennis J Selkoe
    Harvard Medical School, Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Nutr Rev 65:S239-43. 2007
    ..While hard work lies ahead, the movement from basic research to the clinic in AD represents a triumph of reductionist biology applied to the most complex of all biological systems, the human cerebral cortex...
  81. ncbi Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin
    Matthew J LaVoie
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 278:37213-22. 2003
    ....
  82. ncbi Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation
    W Taylor Kimberly
    Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:35113-7. 2002
    ....
  83. ncbi Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study
    Hongliu Ding
    Center for Neurologic Diseases, Harvard Medical School and Brigham and Women s Hospital, Cambridge, Massachusetts, USA
    Mov Disord 26:2283-6. 2011
    ..Mutations in the α-synuclein gene (SNCA) cause autosomal dominant forms of Parkinson's disease, but the substantial risk conferred by this locus to the common sporadic disease has only recently emerged from genome-wide association studies...
  84. ncbi Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes
    Olivia I Okereke
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Psychoneuroendocrinology 33:455-61. 2008
    ....
  85. ncbi Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor
    Matthew L Hemming
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Biol Chem 280:37644-50. 2005
    ..Our data encourage further analyses of the ACE gene for disease association and raise the question of whether currently prescribed ACE inhibitors could elevate cerebral Abeta levels in humans...
  86. ncbi Deciphering the molecular basis of memory failure in Alzheimer's disease
    Dominic M Walsh
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Neuron 44:181-93. 2004
    ..Accordingly, attempts to slow memory and cognitive loss by decreasing cerebral Abeta levels have entered human trials...
  87. ncbi Purification and characterization of the human gamma-secretase complex
    Patrick C Fraering
    Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Biochemistry 43:9774-89. 2004
    ....
  88. ncbi Defining molecular targets to prevent Alzheimer disease
    Dennis J Selkoe
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
    Arch Neurol 62:192-5. 2005
  89. ncbi Resolving controversies on the path to Alzheimer's therapeutics
    Dennis J Selkoe
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 17:1060-5. 2011
    ....
  90. ncbi Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis
    Kim A Celone
    Memory Disorders Unit, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 26:10222-31. 2006
    ..These data may also provide functional evidence of the interaction between neocortical and medial temporal lobe pathology in early AD...
  91. ncbi Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration
    Dominic M Walsh
    Department of Neurology, Harvard Medical School, Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Protein Pept Lett 11:213-28. 2004
    ..With particular reference to AD and PD, we review recent evidence that soluble oligomers are the principal pathogenic species that drive neuronal dysfunction...
  92. ncbi Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet
    Cynthia A Lemere
    Center for Neurologic Diseases, HIM 622, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02215, USA
    Am J Pathol 165:283-97. 2004
    ..The findings further support Abeta immunotherapy as a potential prevention and treatment of AD...
  93. ncbi Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria
    Malcolm A Leissring
    Center for Neurologic Diseases, Department of Neurology, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    Biochem J 383:439-46. 2004
    ..Our results identify new mechanisms regulating the subcellular localization of IDE and suggest previously unrecognized roles for IDE within mitochondria...
  94. ncbi Amyloid-lowering isocoumarins are not direct inhibitors of gamma-secretase
    William P Esler
    Nat Cell Biol 4:E110-1; author reply E111-2. 2002
  95. ncbi Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide
    Christian Haass
    Adolf Butenandt Institute, Department of Biochemistry, Laboratory for Alzheimer s and Parkinson s Disease Research, Ludwig Maximilians University, 80336 Munich, Germany
    Nat Rev Mol Cell Biol 8:101-12. 2007
    ..Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins...
  96. ncbi Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization
    Igor Klyubin
    Institute of Neuroscience and Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland
    J Neurosci 28:4231-7. 2008
    ..Abeta monomer isolated from human CSF did not affect long-term potentiation. These results strongly support a strategy of passive immunization against soluble Abeta oligomers in early Alzheimer's disease...
  97. ncbi Toward a remembrance of things past: deciphering Alzheimer disease
    Dennis J Selkoe
    Department of Neurology, Harvard Medical School, USA
    Harvey Lect 99:23-45. 2003
  98. ncbi A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma
    David L Craft
    Operations Research Center, MIT, Cambridge, MA 02139, USA
    Bull Math Biol 64:1011-31. 2002
    ..Hence, great care must be taken when interpreting these biomarkers...
  99. ncbi Presenilin-1-mediated retention of APP derivatives in early biosynthetic compartments
    Marloes Réchards
    Cell Microscopy Center, Department of Cell Biology, University Medical Center and Institute for Biomembranes, 3584 CX Utrecht, The Netherlands
    Traffic 7:354-64. 2006
    ..Malfunctioning of PS-1 in this role may have important consequences for the progress of AD...
  100. ncbi Intraneuronal Abeta42 accumulation in Down syndrome brain
    Chica Mori
    Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    Amyloid 9:88-102. 2002
    ..We conclude that Abeta42 accumulates intracellularly prior to extracellular Abeta deposition in Down syndrome, and that subsequent maturation of extracellular Abeta deposits elicits inflammatory responses andprecedes NFTs...
  101. ncbi Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes
    Marloes Réchards
    Department of Cell Biology, University Medical Center and Institute for Biomembranes, Center for Biomedical Genetics, Utrecht University, 3584 CX Utrecht, The Netherlands
    Traffic 4:553-65. 2003
    ....